Full Text View
Tabular View
Study Results
Related Studies
Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer
This study has been terminated.
Study NCT00063934   Information provided by National Cancer Institute (NCI)

First Received on July 8, 2003.   Last Updated on December 19, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Male Breast Cancer
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer
Additional conditions recognized in this trial
Breast Neoplasms
Breast Neoplasms, Male
More general conditions related to this trial
Breast Diseases
Neoplasms
Neoplasms by Site
Skin Diseases
Interventions listed in this trial
oblimersen sodium
doxorubicin hydrochloride
docetaxel
filgrastim
pegfilgrastim
therapeutic conventional surgery
pharmacological study
laboratory biomarker analysis
Additional drug interventions recognized in this trial
Doxorubicin
Lenograstim
More general drug interventions related to this trial
Adjuvants, Immunologic
Antibiotics, Antineoplastic
Antineoplastic Agents
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services